CD26: a key molecule in immune regulation and autoimmune diseases

References

• Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev 1998;161:55–70.
   PubMed Web of Science ®Google Scholar
• Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunc-tional integral membrane and secreted protein of activated lym-phocytes. Scand J Immunol 2001;54: 249–64.
   Google Scholar
• Tanaka T, Camerini D, Seed B, Torimoto Y, Dang NH, Kameoka J, et al. Cloning and functional expression of the T cell activation antigen CD26. J Immunol 1992;149:481–6.
   PubMed Web of Science ®Google Scholar
• Brenner S. The molecular evolution of genes and proteins: a tale of two serines. Nature 1988;334:528–30.
   PubMed Web of Science ®Google Scholar
• Hong W, Doyle D. cDNA cloning for a bile canaliculus domain- 25. specific membrane glycoprotein of rat hepatocytes. Proc Natl Acad Sci USA 1987;84:7962–6.
   PubMed Web of Science ®Google Scholar
• Marguet D, Bernard AM, Vivier I, Darmoul D, Naquet P, Pierres M. cDNA cloning for mouse thymocyte-activating molecule. A 26. multifunctional ecto-dipeptidyl peptidase IV (CD26) included in a subgroup of serine proteases. J Biol Chem 1992;267:2200–8.
   Google Scholar
• Iwata S, Morimoto C. CD26/dipeptidyl peptidase IV in context. 27. The different roles of a multifunctional ectoenzyme in malignant transformation. J Exp Med 1999;190: 301–6.
   Google Scholar
• Dang NH, Morimoto C. CD26: an expanding role in immune regulation and cancer. Histol Histopathol 2002;17:1213–26.
   PubMed Web of Science ®Google Scholar
• Haller DA, Fox DA, Manning ME, Schlossman SF, Reinherz EL, 28. Weiner HL. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med 1985;312:1405–11.
   Google Scholar
• Eguchi K, Ueki Y, Shimomura C, Otsubo T, Nakao H, Migita K, et al. Increment in the Tal + cells in the peripheral blood and thyroid 29. tissue of patients with Graves' disease. J Immunol 1989;142:4233–40.
   Google Scholar
• Mizokami A, Eguchi K, Kawakami A, Ida H, Kawabe Y, Tsukada T, et al. Increased population of high fluorescence 1F7 (CD26) antigen on T cells in synovial fluid of patients with rheumatoid 30. arthritis. J Ftheumatol 1996;23:2022–6.
   Google Scholar
• Dang NH, Torimoto Y, Deusch K, Schlossman SF, Morimoto C. Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. J Immunol 31. 1990;144: 4092–100.
   Google Scholar
• De Meester I, Korom S, Van Damme J, Scharpe S. CD26, let it cut or cut it down. Immunol Today 1999;20:367–75.
   PubMedGoogle Scholar
• Morimoto C, Torimoto Y, Levinson G, Rudd CE, Schrieber M, Dang NH, et al. 1F7, a novel cell surface molecule, involved in 32. helper function of CD4 cells. J Immunol 1989;143: 3430–9.
   Google Scholar
• Willheim M, Ebner C, Baier K, Kern W, Schrattbauer K, Thien R, et al. Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T(H1) 33. subsets. J Allergy Clin Immunol 1997;100:348–55.
   PubMed Web of Science ®Google Scholar
• Dang NH, Torimoto Y, Shimamura K, Tanaka T, Daley JF, Schlossman SF, et al. 1F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 path- 34. ways of human thymocyte activation. J Immunol 1991;147:2825–32.
   Google Scholar
• Dang NH, Torimoto Y, Sugita K, Daley JF, Schow P, Prado C, et al. Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activa- 35. tion. J Immunol 1990;145:3963–71.
   Google Scholar
• Torimoto Y, Dang NH, Vivier E, Tanaka T, Schlossman SF, Morimoto C. Coassociation of CD26 (dipeptidyl peptidase IV) 36. with CD45 on the surface of human T lymphocytes. J Immunol 1991;147:2514–7.
   Google Scholar
• Hegen M, Kameoka J, Dong RP, Schlossman SF, Morimoto C. 37. Cross-linking of CD26 by antibody induces tyrosine phosphoryla-tion and activation of mitogen-activated protein kinase. Immunol-ogy 1997;90: 257–64.
   Google Scholar
• Ishii T, Ohnuma K, Murakami A, Takasawa N, Kobayashi S, Dang 38. NH, et al. CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. Proc Natl Acad Sci USA 2001;98: 12138–43.
   Google Scholar
• Flentke GR, Munoz E, Huber BT, Plant AG, Kettner CA, Bachovchin WW. Inhibition of dipeptidyl aminopeptidase IV (DP- 39. IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl Acad Sci USA 1991;88:1556-9.40.
   Google Scholar
• Schon E, Jahn S, Kiessig ST, Demuth HU, Neubert K, Barth A, et al. The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthe- 41. sis in vitro. Eur J Immunol 1987;17:1821–6.
   Google Scholar
• Reinhold D, Bank U, Buhling F, Lendeckel U, Faust J, Neubert K, et al. Inhibitors of dipeptidyl peptidase IV induce secretion of 42. transforming growth factor-beta-1 in PWM-stimulated PBMC and T cells. Immunology 1997;91:354–60.
   Google Scholar
• Steinbrecher A, Reinhold D, Quigley L, Gado A, Tresser N, Izikson L, et al. Targeting dipeptidyl peptidase IV (CD26) sup- 43. presses autoimmune encephalomyelitis and up-regulates TGF-beta-1 secretion in vivo. J Immunol 2001;166:2041–8.
   Google Scholar
• Korom S, De Meester I, Stadlbauer TH, Chandraker A, Schaub M, Sayegh MH, et al. Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients. Transplantation 1997;63:1495�500.
   Web of Science ®Google Scholar
• Tanaka S, Murakami T, Horikawa H, Sugiura M, Kawashima K, Sugita T. Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV. Int J Immunopharmacol 1997;19:15�24.
   Web of Science ®Google Scholar
• Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)- mediated cleavage. J Exp Med 1997;186:1865�72.
   Web of Science ®Google Scholar
• Shioda T, Kato H, Ohnishi Y, Tashiro K, Ikegawa M, Nakayama EE, et al. Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci USA 1998;95:6331�6.
   Web of Science ®Google Scholar
• Ohtsuki T, Hosono O, Kobayashi H, Munakata Y, Souta A, Shioda T, et al. Negative regulation of the anti-human immunodeficiency virus and chemotactic activity of human stromal cell-derived factor1alpha by CD26/dipeptidyl peptidase IV. FEBS Lett 1998;431:236�40.
   Web of Science ®Google Scholar
• Proost P, Menten P, Struyf S, Schutyser E, De Meester I, Van Damme J. Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist. Blood 2000;96:1674�80.
   Google Scholar
• Iwata S, Yamaguchi N, Munakata Y, Ikushima H, Lee JF, Hosono O, et al. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int Immunol 1999;11:417�26.
   Web of Science ®Google Scholar
• Tanaka T, Kameoka J, Yaron A, Schlossman SF, Morimoto C. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc Natl Acad Sci USA 1993;90:a4586�90.
   Google Scholar
• Tanaka T, Duke-Cohan JS, Kameoka J, Yaron A, Lee I, Schlossman SF, et al. Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV. Proc Natl Acad Sci USA 1994;91:3082�6.
   Web of Science ®Google Scholar
• Ohnuma K, Munakata Y, Ishii T, Iwata S, Kobayashi S, Hosono O, et al. Soluble CD26/dipeptidyl peptidase IV induces T cell proliferation through CD86 up-regulation on APCs. J Immunol2001;167:6745�55.
   Web of Science ®Google Scholar
• Ashwell JD, D�Oro U. CD45 and Src-family kinases: and now for something completely different. Immunol Today 1999;20:412�a6.
   Google Scholar
• Alexander DR. The CD45 tyrosine phosphatase: a positive and negative regulator of immune cell function. Semin Immunol2000;12:349�59.
   Web of Science ®Google Scholar
• Ikushima H, Munakata Y, Ishii T, Iwata S, Terashima M, Tanaka H, et al. Internalization of CD26 by mannose 6-phosphate/insulinlike growth factor II receptor contributes to T cell activation. Proc Natl Acad Sci USA 2000;97:8439�44.
   Web of Science ®Google Scholar
• Ikushima H, Munakata Y, Iwata S, Ohnuma K, Kobayashi S, Dang NH, et al. Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6- phosphate/insulin-like growth factor II receptor. Cell Immunol2002;215:106�10.
   Web of Science ®Google Scholar
• Kameoka J, Tanaka T, Nojima Y, Schlossman SF, Morimoto C. Direct association of adenosine deaminase with a T cell activation antigen, CD26. Science 1993;261: 466�9.
   Google Scholar
• Morrison ME, Vijayasaradhi S, Engelstein D, Albino AP, Houghton AN. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Meda1993;177:1135�43.
   Google Scholar
• Franco R, Valenzuela A, Lluis C, Blanco J. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol Rev 1998;161:27�42.
   Web of Science ®Google Scholar
• Dong RP, Kameoka J, Hegen M, Tanaka T, Xu Y, Schlossman SF, et al. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol 1996;156:1349�55.
   Web of Science ®Google Scholar
• Herrera C, Morimoto C, Blanco J, Mallol J, Arenzana F, Lluis C, et al. Comodulation of CXCR4 and CD26 in human lymphocytes. J Biol Chem 2001;276:19532�9.
   Web of Science ®Google Scholar
• Proost P, Struyf S, Schots D, Durinx C, Wuyts A, Lenaerts JP, et al. Processing by CD26/dipeptidyl-peptidase IV reduces the chemot-actic and anti-HIV-1 activity of stromal-cell-derived factor-lalpha. FEBS Lett 1998;432:73–6.
   PubMed Web of Science ®Google Scholar
• Proost P, De Meester I, Schots D, Struyf S, Lambeir AM, Wuyts A, et al. Amino-terminal truncation of chemokines by CD26/ dipeptidyl-peptidase IV. Conversion of FtANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem 1998;273: 7222–7.
   Google Scholar
• Struyf S, Proost P, Schots D, De Clercq E, Opdenakker G, Lenaerts JP, et al. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. J Immunol 1999;162: 4903–9.
   Google Scholar
• Proost P, Struyf S, Schots D, Opdenakker G, Sozzani S, Allavena P, et al. Truncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 1999;274:3988–93.
   PubMed Web of Science ®Google Scholar
• Lambeir AM, Proost P, Durimc C, Bal G, Senten K, Augustyns K, et al. Kinetic investigation of chemokine truncation by CD26/ dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem 2001;276:29839–45.
   PubMed Web of Science ®Google Scholar
• Struyf S, Menten P, Lenaerts JP, Put W, D'Haese A, De Clercq E, et al. Diverging binding capacities of natural LD78beta isoforms of macrophage inflammatory protein-lalpha to the CC chemokine receptors 1,3 and 5 affect their anti-HIV-1 activity and chemotac-tic potencies for neutrophils and eosinophils. Eur J Immunol 2001;31: 2170–8.
   Google Scholar
• Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G, et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001;98:3554–61.
   PubMed Web of Science ®Google Scholar
• Nakao H, Eguchi K, Kawakami A, Migita K, Otsubo T, Ueki Y, et al. Increment of Tal-positive cells in peripheral blood from patients with rheumatoid arthritis. J Ftheumatol 1989;16:904–10.
   Google Scholar
• Khoury SJ, Guttmann CR, Orav EJ, Kikinis R, Jolesz FA, Weiner HL. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch Neurol 2000;57:1183–9.
   PubMedGoogle Scholar
• Muscat C, Bertotto A, Agea E, Bistoni 0, Ercolani R, Tognellini R, et al. Expression and functional role of 1F7 (CD26) antigen on peripheral blood and synovial fluid T cells in rheumatoid arthritis patients. Clin Exp Immunol 1994;98: 252–6.
   Google Scholar
• Gerli R, Muscat C, Bertotto A, Bistoni 0, Agea E, Tognellini R, et al. CD26 surface molecule involvement in T cell activation and lymphokine synthesis in rheumatoid and other inflammatory synovitis. Clin Immunol Immunopathol 1996;80: 31–7.
   Google Scholar
• Masuyama J, Berman JS, Cruikshank WW, Morimoto C, Center DM. Evidence for recent as well as long-term activation of T cells migrating through endothelial cell monolayers in vitro. J Immunol 1992;148:1367–74.
   Google Scholar
• Brezinschek RI, Lipsky PE, Galea P, Vita R, Oppenheimer-Marks N. Phenotypic characterization of CD4+ T cells that exhibit a transendothelial migratory capacity. J Immunol 1995;154: 3062–77.
   Google Scholar
• Luster AD. Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436–45.
   PubMed Web of Science ®Google Scholar
• Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392: 565–8.
   PubMed Web of Science ®Google Scholar
• Ward SG, Westwick J. Chemokines: understanding their role in T-lymphocyte biology. Biochem J 1998;333(Pt 3):457–70.
   PubMed Web of Science ®Google Scholar
• Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science 1999;286:2098–102.
   PubMed Web of Science ®Google Scholar
• Kubota T, Ezuka H, Bachovchin WW, Stollar BD. Dipeptidyl peptidase IV (DP IV) activity in serum and on lymphocytes of MRL/Mp-lpr/lpr mice correlates with disease onset. Clin Exp Immunol 1994;96:292–6.
   PubMed Web of Science ®Google Scholar
• Hagihara M, Ohhashi M, Nagatsu T. Activities of dipeptidyl peptidase II and dipeptidyl peptidase IV in mice with lupus erythematosus-like syndrome and in patients with lupus erythema-tosus and rheumatoid arthritis. Clin Chem 1987;33:1463–5.
   Google Scholar
• Kobayashi H, Hosono 0, Mimori T, Kawasaki H, Dang NH, Tanaka H, et al. Reduction of serum-soluble CD26/dipeptidyl pep-tidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus. J Ftheumatol 2002;29: 1858–66.
   Google Scholar
• Cordero 0J, Salgado FJ, Mera-Varela A, Nogueira M. Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Ftheumatol Int 2001;21: 69–74.
   Google Scholar
• Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med 1985;313:79–84.
   Google Scholar
• van Noesel CJ, Gruters RA, Terpstra FG, Schellekens PT, van Lier RA, Miedema F. Functional and phenotypic evidence for a selec-tive loss of memory T cells in asymptomatic human immunodefi-ciency virus-infected men. J Clin Invest 1990;86:293–9.
   PubMed Web of Science ®Google Scholar
• Blazquez MV, Madueno JA, Gonzalez R, Jurado R, Bachovchin WW, Pena J, et al. Selective decrease of CD26 expression in T cells from HIV-1-infected individuals. J Immunol 1992;149:3073–7.
   PubMed Web of Science ®Google Scholar
• Gougeon ML, Lecoeur H, Callebaut C, Jacotot E, Dulioust A, Roue R, et al. Selective loss of the CD4+/CD26+ T-cell subset during HIV infection. Res Immunol 1996;147:5–8.
   PubMedGoogle Scholar
• Cullen BR. Does HIV-1 Tat induce a change in viral initiation rights? Cell 1993;73:417–20.
   PubMed Web of Science ®Google Scholar
• Viscidi RP, Mayur K, Lederman HM, Frankel AD. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science 1989;246:1606–8.
   PubMed Web of Science ®Google Scholar
• Gutheil WG, Subramanyam M, Flentke GR, Sanford DG, Munoz E, Huber BT, et al. Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity. Proc Natl Acad Sci USA 1994;91:6594–8.
   PubMed Web of Science ®Google Scholar
• Hosono 0, Homma T, Kobayashi H, Munakata Y, Nojima Y, Iwamoto A, et al. Decreased dipeptidyl peptidase IV enzyme activ-ity of plasma-soluble CD26 and its inverse correlation with HIV-1 RNA in HIV-1 infected individuals. Clin Immunol 1999;91: 283–95.
   Google Scholar
• Ohnuma K, Ishii T, Iwata S, Hosono 0, Kawasaki H, Uchiyama M, et al. Gl/S cell cycle arrest provoked in human T cells by antibody to CD26. Immunology 2002;107: 325–33.
   Google Scholar
• Falcioni F, Shah H, Vidovic D, Morimoto C, Belunis C, Bolin D, et al. Influence of CD26 and integrins on the antigen sensitivity of human memory T cells. Hum Immunol 1996;50:79–90.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Corte G, Ramarli D, van Lint MT, Frassoni F, Marmont A. Intravenous monoclonal antibody (BT 5/9) for the treatment of acute graft-versus-host disease. Acta Haematol 1985; 73:185–6.
   Google Scholar
• de Meester I, Scharpe S, Vanham G, Bosmans E, Heyligen H, Vanhoof G, et al. Antibody binding profile of purified and cell-bound CD26. Designation of BT5/9 and TA5.9 to the CD26 clus-ter. Immunobiology 1993;188:145–58.
   Google Scholar
• Khanna AK, Hosenpud JD. In vitro and in vivo transfection of p21 gene enhances cyclosporin A-mediated inhibition of lymphocyte proliferation. J Immunol 2000;165:1882–8.
   PubMed Web of Science ®Google Scholar